Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients

Next Previous
X
Search
Trial Profile

Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VL 2397 (Primary) ; Amphotericin B liposomal; Isavuconazole; Voriconazole; Voriconazole
  • Indications Aspergillosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Vical

    • Most Recent Events

    • 19 Feb 2019 According to a Vical media release, the company has decided to discontinue this trial due to low patient accrual rates and the company's decision to pursue strategic alternative review process to conserve cash.
    • 19 Feb 2019 Status changed from recruiting to discontinued, according to a Vical media release.
    • 07 Aug 2018 According to a Vical media release, top-line data are expected in 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top